Shamburg News · 8-K filed Nov 13, 2026, 5:00 PM EST

Beyond Air Reports Quarterly Revenue of $2.3 Million and Reaffirms 2026 and 2027 Revenue Guidance

XAIR · Beyond Air, Inc.

  • Earnings
  • Financial statements
  • Acquisition
  • Other event
  • Reg FD disclosure
  • Materiality: high

Beyond Air, Inc. reported revenue of $2.3 million for the quarter ended September 30, 2026, compared with $1.8 million a year earlier, and a net loss attributable to the company of $7.8 million, or $3.76 per basic and diluted share. The company reaffirmed revenue guidance of $8 million for calendar 2026 and $16 million to $18 million for calendar 2027, the latter contingent on FDA approval of its second-generation LungFit PH system. The filing also disclosed a planned fiscal year-end transition to December 31 and an agreement for UNIVO Pharmaceutical Industries to acquire the company's controlling interest in NeuroNOS Israel Ltd.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 9.01, accession 0001493152-26-051810.

Written from the filing by Shamburg Markets. Figures are as reported by the company.